Human Chorionic Gonadotropin Global Market Report 2025

Description

Human chorionic gonadotropin (hCG) is a hormone produced during pregnancy by the placenta shortly after embryo implantation in the uterus. It is essential for sustaining pregnancy by stimulating the corpus luteum in the ovary to produce progesterone, which maintains the uterine lining and prevents its breakdown.

The primary technologies for producing hCG are natural source extraction and recombinant technology. Recombinant technology involves combining DNA fragments from various organisms to create new genetic combinations. hCG is used in treating female infertility, oligospermia, male hypogonadism, and other conditions. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by fertility clinics, research institutions, and other users.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The human chorionic gonadotropin market research report is one of a series of new reports from The Business Research Company that provides human chorionic gonadotropin market statistics, including human chorionic gonadotropin industry global market size, regional shares, competitors with a human chorionic gonadotropin market share, detailed human chorionic gonadotropin market segments, market trends, and opportunities, and any further data you may need to thrive in the human chorionic gonadotropin industry. This human chorionic gonadotropin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human chorionic gonadotropin market size has grown strongly in recent years. It will grow from $0.95 billion in 2024 to $1.02 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to the rise in the prevalence of hypogonadism in the geriatric population, increase in awareness toward HCG among healthcare professionals and patients, rise in popularity of fertility tourism, increase in the geriatric population, and increase in affordability and improvement in healthcare facilities.

The human chorionic gonadotropin market size is expected to see strong growth in the next few years. It will grow to $1.41 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to the increasing incidence of infertility, surging prevalence of polycystic ovary syndrome, increasing female infertility, and rising usage of HCG in veterinary medicine. Major trends in the forecast period include advancements in pregnancy detection, innovative drug formulations, technological integration, focus on research and development, and product innovation.

The forecast of 8.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of Human Chorionic Gonadotropin(hCG) hormone therapies sourced from Switzerland and Denmark, thereby delaying fertility treatments and elevating reproductive endocrinology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

An increasing rate of infertility is anticipated to propel the growth of the human chorionic gonadotropin (hCG) market in the coming years. Infertility, defined as the inability to conceive after at least one year of consistent, unprotected intercourse, is on the rise. Contributing factors include delayed childbearing, lifestyle changes, environmental exposures, and medical conditions. Human chorionic gonadotropin (hCG) is utilized in infertility treatments to stimulate ovulation in women and support testosterone production in men, facilitating egg release and improving fertility outcomes. For instance, in April 2023, the World Health Organization reported that infertility affects approximately 17.5% of the adult population, or roughly one in six people globally, underscoring the urgent need for accessible, high-quality fertility care. Consequently, the rising infertility rate is driving the growth of the human chorionic gonadotropin market.

Key players in the human chorionic gonadotropin market are focusing on the development of innovative products, such as pregnancy detection kits, to enhance diagnostic accuracy, improve patient outcomes, and broaden market reach. Pregnancy detection kits are designed to confirm pregnancy by detecting human chorionic gonadotropin (hCG) in the body. For example, in June 2022, Proov, a US-based medical equipment manufacturer, introduced new hCG tests for early pregnancy detection, enabling women to verify pregnancy up to six days before their expected period. These tests identify hCG in urine with a reliability rate exceeding 99%, providing a dependable and accessible method for women to monitor their pregnancy status earlier than traditional tests and make informed reproductive health decisions.

In September 2023, Lupin Limited, an India-based pharmaceutical company, acquired five brands from Menarini for an undisclosed sum. This acquisition aims to expand Lupin's portfolio and strengthen its position in key therapeutic areas by integrating five established brands from Menarini. Menarini Group, an Italy-based pharmaceutical and diagnostics company, offers services related to human chorionic gonadotropin (hCG).

Major companies operating in the human chorionic gonadotropin market are Pfizer Inc., Merck & Co Inc., Novartis AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Janssen Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Menarini Group, Cipla Limited, Hikma Pharmaceuticals plc, Ferring Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Lupin Limited, Shenzhen Hepalink Pharmaceutical Group Co. Ltd., Scripps Laboratories Inc., Aspen Pharmacare Holdings Limited, Corona Remedies Pvt Ltd., Sanzyme Private Limited, Biocare Medical LLC, Lee BioSolutions Inc., MyBioSource Inc.

North America was the largest region in the human chorionic gonadotropin market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human chorionic gonadotropin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the human chorionic gonadotropin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human chorionic gonadotropin market includes revenues earned by entities by providing services such as fertility treatments, hormone level monitoring, assisted reproductive technologies (ART), and pregnancy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Chorionic Gonadotropin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human chorionic gonadotropin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human chorionic gonadotropin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human chorionic gonadotropin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Technology: Natural Source Extraction; Recombinant Technology
2) By Therapeutic Area: Female Infertility Treatment; Oligospermic Treatment; Male Hypogonadism; Other Therapeutic Areas
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Fertility Clinics; Research Institutions; Other End Users
Subsegments:
1) By Natural Source Extraction: Extraction From Pregnant Women's Urine; Extraction From Animal Sources
2) By Recombinant Technology: Recombinant Hcg; Recombinant Hcg For Therapeutic Use; Recombinant Hcg For Diagnostic Applications
Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Novartis AG; Bristol-Myers Squibb Company; Fresenius Kabi AG; Janssen Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; Sun Pharmaceutical Industries Limited; Menarini Group; Cipla Limited; Hikma Pharmaceuticals plc; Ferring Pharmaceuticals Inc.; Intas Pharmaceuticals Ltd.; Zydus Lifesciences Limited; Lupin Limited; Shenzhen Hepalink Pharmaceutical Group Co. Ltd.; Scripps Laboratories Inc.; Aspen Pharmacare Holdings Limited; Corona Remedies Pvt Ltd.; Sanzyme Private Limited; Biocare Medical LLC; Lee BioSolutions Inc.; MyBioSource Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r30422u

1. Executive Summary

2. Human Chorionic Gonadotropin Market Characteristics

3. Human Chorionic Gonadotropin Market Trends And Strategies

4. Human Chorionic Gonadotropin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Human Chorionic Gonadotropin Growth Analysis And Strategic Analysis Framework

5.1. Global Human Chorionic Gonadotropin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Human Chorionic Gonadotropin Market Growth Rate Analysis
5.4. Global Human Chorionic Gonadotropin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Human Chorionic Gonadotropin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Human Chorionic Gonadotropin Total Addressable Market (TAM)

6. Human Chorionic Gonadotropin Market Segmentation

6.1. Global Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Natural Source Extraction
Recombinant Technology
6.2. Global Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Female Infertility Treatment
Oligospermic Treatment
Male Hypogonadism
Other Therapeutic Areas
6.3. Global Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Human Chorionic Gonadotropin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fertility Clinics
Research Institutions
Other End Users
6.5. Global Human Chorionic Gonadotropin Market, Sub-Segmentation Of Natural Source Extraction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Extraction From Pregnant Women's Urine
Extraction From Animal Sources
6.6. Global Human Chorionic Gonadotropin Market, Sub-Segmentation Of Recombinant Technology, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Hcg
Recombinant Hcg For Therapeutic Use
Recombinant Hcg For Diagnostic Applications

7. Human Chorionic Gonadotropin Market Regional And Country Analysis

7.1. Global Human Chorionic Gonadotropin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Human Chorionic Gonadotropin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Chorionic Gonadotropin Market

8.1. Asia-Pacific Human Chorionic Gonadotropin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Chorionic Gonadotropin Market

9.1. China Human Chorionic Gonadotropin Market Overview
9.2. China Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Chorionic Gonadotropin Market

10.1. India Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Chorionic Gonadotropin Market

11.1. Japan Human Chorionic Gonadotropin Market Overview
11.2. Japan Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Chorionic Gonadotropin Market

12.1. Australia Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Chorionic Gonadotropin Market

13.1. Indonesia Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Chorionic Gonadotropin Market

14.1. South Korea Human Chorionic Gonadotropin Market Overview
14.2. South Korea Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Chorionic Gonadotropin Market

15.1. Western Europe Human Chorionic Gonadotropin Market Overview
15.2. Western Europe Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Chorionic Gonadotropin Market

16.1. UK Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Chorionic Gonadotropin Market

17.1. Germany Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Chorionic Gonadotropin Market

18.1. France Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Chorionic Gonadotropin Market

19.1. Italy Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Chorionic Gonadotropin Market

20.1. Spain Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Chorionic Gonadotropin Market

21.1. Eastern Europe Human Chorionic Gonadotropin Market Overview
21.2. Eastern Europe Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Chorionic Gonadotropin Market

22.1. Russia Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Chorionic Gonadotropin Market

23.1. North America Human Chorionic Gonadotropin Market Overview
23.2. North America Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Chorionic Gonadotropin Market

24.1. USA Human Chorionic Gonadotropin Market Overview
24.2. USA Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Chorionic Gonadotropin Market

25.1. Canada Human Chorionic Gonadotropin Market Overview
25.2. Canada Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Chorionic Gonadotropin Market

26.1. South America Human Chorionic Gonadotropin Market Overview
26.2. South America Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Chorionic Gonadotropin Market

27.1. Brazil Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Chorionic Gonadotropin Market

28.1. Middle East Human Chorionic Gonadotropin Market Overview
28.2. Middle East Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Chorionic Gonadotropin Market

29.1. Africa Human Chorionic Gonadotropin Market Overview
29.2. Africa Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Chorionic Gonadotropin Market Competitive Landscape And Company Profiles

30.1. Human Chorionic Gonadotropin Market Competitive Landscape
30.2. Human Chorionic Gonadotropin Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Human Chorionic Gonadotropin Market Other Major And Innovative Companies

31.1. Janssen Pharmaceuticals Inc.
31.2. Teva Pharmaceutical Industries Ltd.
31.3. Sandoz International GmbH
31.4. Sun Pharmaceutical Industries Limited
31.5. Menarini Group
31.6. Cipla Limited
31.7. Hikma Pharmaceuticals plc
31.8. Ferring Pharmaceuticals Inc.
31.9. Intas Pharmaceuticals Ltd.
31.10. Zydus Lifesciences Limited
31.11. Lupin Limited
31.12. Shenzhen Hepalink Pharmaceutical Group Co. Ltd.
31.13. Scripps Laboratories Inc.
31.14. Aspen Pharmacare Holdings Limited
31.15. Corona Remedies Pvt Ltd.

32. Global Human Chorionic Gonadotropin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Chorionic Gonadotropin Market

34. Recent Developments In The Human Chorionic Gonadotropin Market

35. Human Chorionic Gonadotropin Market High Potential Countries, Segments and Strategies

35.1 Human Chorionic Gonadotropin Market In 2029 - Countries Offering Most New Opportunities
35.2 Human Chorionic Gonadotropin Market In 2029 - Segments Offering Most New Opportunities
35.3 Human Chorionic Gonadotropin Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer